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Background
Cancer vaccines attracted a lot of attention as an alter-
native/adjuvant therapeutic approach for patients with
advanced metastatic cancer. Preclinical studies showed
that tumors can evade the adaptive immune response by
activation of immune checkpoints in the tumor micro-
environment. Tumors may naturally up-regulate immu-
nosuppressive ligands in response to the host immunity,
making these immune checkpoints critical components
of a tumor-associated immune signatures and useful
prognostic biomarkers since their immunosuppressive
function can be reversed by specific and drugable inhibi-
tors. We postulate that the mechanism(s) of resistance
to adaptive immunity may be distinct between the
genetically distinct MSI+ and CSI+ CRC.
Results
Thirty three tumor/normal pairs, including 7 MSIhigh
samples have been analyzed for their immunologic envir-
onment, including lymphocytes subsets, cytokine produc-
tion, immune checkpoint expression and myeloid
populations. Flow cytometry analysis showed Lag-3 or
Tim-3 predominant patients in CD4+ and CD8+ cells
and these two immune-checkpoints behave in a mutually
exclusive pattern. CD4+ cells made higher amounts of
IL-17 in MSIlow patients compared to the prognostically
better MSIhigh patients group. Conversely, the expres-
sion of Tim-3 was higher on CD4+ cells from MSIhigh
patients suggesting a more active state of these lympho-
cytes. In these two genetically distinct CRC populations,
immune checkpoints seem to have a different functional
significance. In MSIlow samples, there is an increased
production of interferon gamma in tumor-infiltrating
T cells (CD4+ and CD8+) versus a decreased production
of this cytokine in cells expressing LAG-3 or TIM-3. On
the contrary, while observing a very strong production of
IFNg in MSIhigh CRC-infiltrating T cells, LAG-3+ or
Tim3+ T cells barely decreased IFNg production. Finally,
according to the PD-1 expression of CD4+ cells in MSI-
high patients, we identified two distinct populations of
lymphocytes which react differently to Lag-3 or Tim-3
expression. A PD-1 high population, which is a stronger
producer of IFNg and is not inhibited by Lag-3 or Tim-3
expression except in the presence of high levels of Lag-3,
and a PD-1 low CD4 population which produces much
lower quantities of IFNg which is suppressed by the pre-
sence of the two mentioned immune-checkpoints.
Conclusions
Our data has direct translational implications for the use
of the MSI vs CSI CRC status to design clinical trials
with relevant immunomodulatory mAbs. Patients with
low expression of PD-1 may therefore be more sensitive
to the LAG-3 or TIM-3 blockade approach.
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